
    
      This study plans to enroll 12 patients to assess the safety and efficacy of C-CAR066.
      Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection.

      The study will include the following sequential phases: Screening, Pre- Treatment (Cell
      Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.
    
  